Allos Therapeutics

  www.allos.com
  www.allos.com

Allos Therapeutics Reviews

2 Reviews
2.1
2 Reviews

Recommend to a friend
Approve of CEO
Allos Therapeutics President, CEO, and Director Paul L. Berns
Paul L. Berns
2 Ratings
  1.  

    Greedy, tone deaf senior management drove company into the ground

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Development in Westminster, CO
    Former Employee - Development in Westminster, CO

    I worked at Allos Therapeutics full-time (more than 3 years)

    Pros

    Paid well for good people
    Some latitude to do your job

    Cons

    Hugely unrealistic corporate goals
    High school clique atmosphere
    Sr Mgmt was so greedy and had such an inflated sense of worth that they burned through capital and squandered opportunities
    Quick to fire only certain people.
    No training
    Bought by Spectrum which is amazingly worse.

    Advice to ManagementAdvice

    Grow up
    You WERE responsible to the staff and company you milked.
    BOD - unspeakable disservice in keeping Paul so far past his prime.

    Doesn't Recommend
    Negative Outlook
    Disapproves of CEO

Allos Therapeutics Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.allos.com
Headquarters Westminster, CO
Size 50 to 149 Employees
Founded 1992
Type Company - Public
Industry Biotech & Pharmaceuticals
Revenue $10 to $25 million (USD) per year

Drug developer Allos Therapeutics is looking for the next big breakthrough in the fight against cancer. The company's first FDA-approved drug, Folotyn (pralatrexate), was launched commercially in the US in 2010 to treat a relatively rare blood cancer called peripheral T-cell lymphoma (PTCL). Allos Therapeutics is also investigating the compound as a potential treatment in other oncology applications, including additional forms of lymphoma; Folotyn is also in clinical trial and research studies for non-small cell lung cancer (NSCLC) and bladder and breast cancers.

Work at Allos Therapeutics? Share Your Experiences

Allos Therapeutics

 
Click to Rate
or